Market Overview:
The global biopharma outsourcing market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing demand for biopharmaceuticals, rising R&D expenditure by pharmaceutical and biotech companies, and growing number of contract research organizations (CROs). In terms of type, the raw material sourcing segment is expected to account for the largest share of the global biopharma outsourcing market in 2018. This can be attributed to the increasing demand for raw materials used in drug discovery and development processes. By application, preclinical development is projected to grow at the highest CAGR during the forecast period owing to rising investments by pharmaceutical and biotech companies in this segment.
Product Definition:
The term "biopharma outsourcing" typically refers to the process of contracting out the manufacturing of biologic drugs to specialized contract manufacturers. This practice has become increasingly common in recent years as biologic drugs have become more complex and expensive to produce.
-Access to specialized manufacturing facilities.
Raw Material Sourcing:
Raw material sourcing is the process of procuring materials to make biopharmaceuticals. The process includes procurement, production, and quality check of raw materials. It also involves determining the most cost-effective way to produce a certain quantity of raw material for a fixed budget. In other words, it's about finding the right partners at the right time with maximum benefits.
Active Pharmaceutical Ingredient:
Active pharmaceutical ingredient (API) is a chemical compound, which has therapeutic properties for treating diseases. It can be derived from natural sources or synthetically. The most commonly used APIs are the antibiotics and insulin for regulating blood sugar levels in patients suffering from diabetes mellitus.
Application Insights:
Drug discovery and clinical trials accounted for the largest share in 2015. Drug discovery is expected to be the fastest-growing application segment over the forecast period owing to increasing R&D spending by biopharmaceutical companies. The rising number of novel drug candidates in preclinical testing and ongoing research activities are also anticipated to contribute significantly towards growth.
Clinical trials is another key application segment that includes a combination of data collection, patient enrollment, treatment planning, study implementation, analysis & interpretation of data as well as writing up results at various stages throughout a trial. Increasing number of clinical trials being conducted across various diseases & conditions is further anticipated to fuel growth during the forecast period.
Preclinical development comprises initial phases where drugs are developed before they go into large scale human studies for proving efficacy and safety profile.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing regional market over the forecast period. The presence of a large number of outsourcing companies in countries, such as China and India, has resulted in this growth. In addition, factors such as favorable government policies for life sciences research and development activities are anticipated to drive the Asia Pacific biopharma outsourcing market during the forecast period.
In 2017, preclinical development was estimated to account for around 40% of all costs involved in drug discovery projects; thus it is considered vital that these costs are recovered through sales or pricing strategies at various stages of clinical trials (Phase I & II).
Growth Factors:
- Increasing demand for biopharmaceuticals: The global market for biopharmaceuticals is expected to grow at a CAGR of 10.8% from 2016 to 2021, reaching a value of 2.8 billion by 2021. This growth is primarily attributed to the increasing prevalence of chronic diseases, rising awareness about available treatments, and technological advancements in the field of biopharmaceuticals.
- Rising R&D expenditure by pharmaceutical companies: Pharmaceutical companies are increasingly allocating more funds towards R&D in order to develop novel therapies and expand their product portfolios. In 2015, the global pharmaceutical industry spent around 7 billion on R&D activities, which is expected to increase at a CAGR of 6% from 2016-2021. This will create opportunities for contract research organizations (CROs) and other service providers involved in drug development processes
Scope Of The Report
Report Attributes
Report Details
Report Title
Biopharma Outsourcing Market Research Report
By Type
Raw Material Sourcing, Active Pharmaceutical Ingredient, Finished Drugs
By Application
Drug Discovery, Clinical Trials, Preclinical Development, Biology Research
By Companies
Sartorius, Emcure Pharmaceuticals, BioPharma Services, Lambda Therapeutic Research, Baxter Healthcare, Keyrus Biopharma, Quintiles, Aptuit, KBI Biopharm, ICON
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
210
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Biopharma Outsourcing Market Report Segments:
The global Biopharma Outsourcing market is segmented on the basis of:
Types
Raw Material Sourcing, Active Pharmaceutical Ingredient, Finished Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Drug Discovery, Clinical Trials, Preclinical Development, Biology Research
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sartorius
- Emcure Pharmaceuticals
- BioPharma Services
- Lambda Therapeutic Research
- Baxter Healthcare
- Keyrus Biopharma
- Quintiles
- Aptuit
- KBI Biopharm
- ICON
Highlights of The Biopharma Outsourcing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Raw Material Sourcing
- Active Pharmaceutical Ingredient
- Finished Drugs
- By Application:
- Drug Discovery
- Clinical Trials
- Preclinical Development
- Biology Research
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biopharma Outsourcing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biopharma outsourcing is the process of contracting with a third-party company to provide services related to the development, manufacture, and/or marketing of pharmaceutical products. These companies may be specialized in certain areas of biotechnology or pharmaceuticals, such as clinical trials or regulatory affairs.
Some of the major players in the biopharma outsourcing market are Sartorius, Emcure Pharmaceuticals, BioPharma Services, Lambda Therapeutic Research, Baxter Healthcare, Keyrus Biopharma, Quintiles, Aptuit, KBI Biopharm, ICON.
The biopharma outsourcing market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Biopharma Outsourcing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Biopharma Outsourcing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Biopharma Outsourcing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Biopharma Outsourcing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Biopharma Outsourcing Market Size & Forecast, 2018-2028
4.5.1 Biopharma Outsourcing Market Size and Y-o-Y Growth
4.5.2 Biopharma Outsourcing Market Absolute $ Opportunity
Chapter 5 Global Biopharma Outsourcing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Biopharma Outsourcing Market Size Forecast by Type
5.2.1 Raw Material Sourcing
5.2.2 Active Pharmaceutical Ingredient
5.2.3 Finished Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Biopharma Outsourcing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Biopharma Outsourcing Market Size Forecast by Applications
6.2.1 Drug Discovery
6.2.2 Clinical Trials
6.2.3 Preclinical Development
6.2.4 Biology Research
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Biopharma Outsourcing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Biopharma Outsourcing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Biopharma Outsourcing Analysis and Forecast
9.1 Introduction
9.2 North America Biopharma Outsourcing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Biopharma Outsourcing Market Size Forecast by Type
9.6.1 Raw Material Sourcing
9.6.2 Active Pharmaceutical Ingredient
9.6.3 Finished Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Biopharma Outsourcing Market Size Forecast by Applications
9.10.1 Drug Discovery
9.10.2 Clinical Trials
9.10.3 Preclinical Development
9.10.4 Biology Research
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Biopharma Outsourcing Analysis and Forecast
10.1 Introduction
10.2 Europe Biopharma Outsourcing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Biopharma Outsourcing Market Size Forecast by Type
10.6.1 Raw Material Sourcing
10.6.2 Active Pharmaceutical Ingredient
10.6.3 Finished Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Biopharma Outsourcing Market Size Forecast by Applications
10.10.1 Drug Discovery
10.10.2 Clinical Trials
10.10.3 Preclinical Development
10.10.4 Biology Research
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Biopharma Outsourcing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Biopharma Outsourcing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Biopharma Outsourcing Market Size Forecast by Type
11.6.1 Raw Material Sourcing
11.6.2 Active Pharmaceutical Ingredient
11.6.3 Finished Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Biopharma Outsourcing Market Size Forecast by Applications
11.10.1 Drug Discovery
11.10.2 Clinical Trials
11.10.3 Preclinical Development
11.10.4 Biology Research
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Biopharma Outsourcing Analysis and Forecast
12.1 Introduction
12.2 Latin America Biopharma Outsourcing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Biopharma Outsourcing Market Size Forecast by Type
12.6.1 Raw Material Sourcing
12.6.2 Active Pharmaceutical Ingredient
12.6.3 Finished Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Biopharma Outsourcing Market Size Forecast by Applications
12.10.1 Drug Discovery
12.10.2 Clinical Trials
12.10.3 Preclinical Development
12.10.4 Biology Research
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Biopharma Outsourcing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Biopharma Outsourcing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Biopharma Outsourcing Market Size Forecast by Type
13.6.1 Raw Material Sourcing
13.6.2 Active Pharmaceutical Ingredient
13.6.3 Finished Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Biopharma Outsourcing Market Size Forecast by Applications
13.10.1 Drug Discovery
13.10.2 Clinical Trials
13.10.3 Preclinical Development
13.10.4 Biology Research
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Biopharma Outsourcing Market: Competitive Dashboard
14.2 Global Biopharma Outsourcing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sartorius
14.3.2 Emcure Pharmaceuticals
14.3.3 BioPharma Services
14.3.4 Lambda Therapeutic Research
14.3.5 Baxter Healthcare
14.3.6 Keyrus Biopharma
14.3.7 Quintiles
14.3.8 Aptuit
14.3.9 KBI Biopharm
14.3.10 ICON
